Literature DB >> 32772601

Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.

Elisabetta Antonioli1, Michela Staderini1, Sofia Pilerci1, Federico Perfetto2, Francesco Cappelli2, Marco Allinovi2,3, Chiara Nozzoli4, Irene Attucci1, Alessandra Buzzichelli1, Maria Messeri1, Alberto Bosi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32772601     DOI： 10.1080/10428194.2020.1802452

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience.

Authors:  Ludovica Fucci; Lorenzo Gensini; Ugo Coppetelli; Elettra Ortu La Barbera; Martina Gentile; Luciano Fiori; Salvatore Perrone; Giuseppe Cimino
Journal:  Leuk Res Rep       Date:  2022-05-30

2.  Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.

Authors:  Francesca Fazio; Luca Franceschini; Valeria Tomarchio; Angela Rago; Maria Grazia Garzia; Luca Cupelli; Velia Bongarzoni; Alessandro Andriani; Svitlana Gumenyuk; Agostino Tafuri; Agostina Siniscalchi; Alfonso Piciocchi; Paolo De Fabritiis; Luca De Rosa; Tommaso Caravita di Toritto; Ombretta Annibali; Maria Cantonetti; Maria Teresa Petrucci
Journal:  EJHaem       Date:  2022-01-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.